文献速递甲状腺疾病

T1bN0M0甲状腺乳头状癌的主动监测

Active Surveillance for T1bN0M0 Papillary Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2019-01-08

该前瞻性研究对比了61例选择主动监测的T1bN0M0甲状腺乳头状癌患者与360例T1aN0M0监测患者及331例T1bN0M0手术患者。平均监测7.4年,T1a与T1b组肿瘤增大率分别为8%和7%(p=0.69),淋巴结转移率分别为0.8%和3%(p=0.10),无显著差异。结论认为主动监测是部分T1bN0M0患者的选择。

要点

  • T1bN0M0与T1aN0M0主动监测的肿瘤增大和淋巴结转移率无显著差异。
  • T1bN0M0中弱钙化和丰富血供是肿瘤增大的危险因素,年轻是淋巴结转移的预测因素。
  • 直径<15mm的T1bN0M0患者术后无复发。

核心结论

  • 主动监测是部分T1bN0M0甲状腺乳头状癌患者的一种选择。

研究设计与样本

  • 前瞻性试验,自1995年起纳入360例T1aN0M0患者进行主动监测。
  • 392例T1bN0M0患者中,61例选择主动监测,331例接受手术。

主要发现

  • 平均主动监测7.4年,T1aN0M0组29例(8%)肿瘤增大,T1bN0M0组4例(7%)增大(p=0.69)。
  • 淋巴结转移在T1aN0M0组3例(0.8%),T1bN0M0组2例(3%)(p=0.10)。
  • T1bN0M0中弱钙化和丰富血供是肿瘤增大的危险因素,年轻是淋巴结转移的预测因素。
  • 立即手术的T1bN0M0患者初始肿瘤平均大小14.5±2.8 mm,大于选择观察者的11.7±1.1 mm(p<0.0001)。
  • 肿瘤直径<15 mm的患者术后无复发。

临床怎么用

  • 对部分T1bN0M0甲状腺乳头状癌患者可考虑主动监测作为手术替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prospective trials of active surveillance for asymptomatic papillary microcarcinoma (T1aN0M0) since the 1990s have shown progression rates of only 5-10%. Late rescue surgery after progression had no deleterious effects on mortality and morbidity. The 2015 American Thyroid Association guidelines approved active surveillance for very low-risk papillary thyroid carcinoma (PTC) as an alternative method to immediate surgery. However, there is no study that evaluates long-term active surveillance for T1b tumors. METHODS: A prospective trial of active surveillance with 360 very low-risk PTC (T1aN0M0) patients has been conducted since 1995. Of the 392 T1bN0M0 patients, 61 selected active surveillance over surgery and eventually participated in this trial, while the remaining 331 patients underwent surgery. To find an appropriate management strategy for patients with T1bN0M0 PTC, the outcomes of active surveillance for T1bN0M0 to T1aN0M0 PTC were investigated and compared, and the outcomes of surgery for T1bN0M0 PTC were studied. RESULTS: After a mean of 7.4 years of active surveillance, 29 (8%) T1aN0M0 tumors and four (7%) T1bN0M0 tumors had increased in size (p = 0.69). Development of lymph node metastasis was seen in three (0.8%) patients and two (3%) patients, respectively (p = 0.10). No significant difference in progression rate was seen between groups. Among T1bN0M0 tumors, weak calcification and rich vascularity were risk factors for tumor-size increase, and younger age was a predictor for the development of lymph node metastasis. Mean initial tumor size was significantly greater in T1bN0M0 patients who underwent immediate surgery (14.5 ± 2.8 mm) than it was in patients who chose observation (11.7 ± 1.1 mm; p < 0.0001). No postoperative recurrence was seen in patients with tumor <15 mm in diameter. CONCLUSIONS: Active surveillance is an option for selected patients with T1bN0M0 PTC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Sakai T, Sugitani I, Ebina A, et al. Active Surveillance for T1bN0M0 Papillary Thyroid Carcinoma. Thyroid. 2019. PMID: 30560718. doi:10.1089/thy.2018.0462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。